HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Planelles, L. Articles by Hahne, M. Search for Related Content PubMed PubMed Citation Articles by Planelles, L. Articles by Hahne, M.

APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival

^* Institut de Génétique Moléculaire de Montpellier, UMR5535, Montpellier, France
^° Department of Statistics and Operation Research, University of Jaén, Spain
^# Laboratory for Experimental Oncology and Radiobiology, Amsterdam Medical Center, Amsterdam, The Netherlands
^@ Service d’Hématologie Biologique, Groupe Hospitalier La Pitié-Salpêtrière, Paris, France

Correspondence: Lourdes Planelles, PhD, Department of Immunology and Oncology, Centro Nacional de Biotecnologia/CSIC, Darwin 3, UAM Campus de Cantoblanco, 28049 Madrid, Spain. Phone: international +34.915854855. Fax: international +34.9.13720493. E-mail: lplanelles{at}cnb.uam.es

APRIL (a proliferation-inducing ligand) and BLyS (B lymphocyte stimulator) expression have been reported in chronic lymphocytic leukemia (CLL) cells. We examined APRIL and BLyS serum levels in CLL patients and evaluated the prognostic significance of APRIL expression on survival.

Key words: LLC, APRIL serum levels, overall survival, prognostic factor.